These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 1603627

  • 1. Enzyme augmentation in moderate to life-threatening Gaucher disease.
    Fallet S, Grace ME, Sibille A, Mendelson DS, Shapiro RS, Hermann G, Grabowski GA.
    Pediatr Res; 1992 May; 31(5):496-502. PubMed ID: 1603627
    [Abstract] [Full Text] [Related]

  • 2. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months.
    Pastores GM, Sibille AR, Grabowski GA.
    Blood; 1993 Jul 15; 82(2):408-16. PubMed ID: 8392397
    [Abstract] [Full Text] [Related]

  • 3. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 15; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 4. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 15; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 5. Enzyme replacement therapy in type I Gaucher disease.
    Kay AC, Saven A, Garver P, Thurston DW, Rosenbloom BF, Beutler E.
    Trans Assoc Am Physicians; 1991 Feb 15; 104():258-64. PubMed ID: 1845151
    [No Abstract] [Full Text] [Related]

  • 6. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J, Szücs FZ, Benkö K, Maródi L.
    Orv Hetil; 2003 Apr 20; 144(16):749-55. PubMed ID: 12778625
    [Abstract] [Full Text] [Related]

  • 7. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.
    Grigorescu Sido P, Drugan C, Cret V, Al-Kzouz C, Denes C, Coldea C, Zimmermann A.
    J Inherit Metab Dis; 2007 Oct 20; 30(5):783-9. PubMed ID: 17703370
    [Abstract] [Full Text] [Related]

  • 8. [Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease].
    Pérez-Calvo JI, Giraldo P, Giralt M.
    Sangre (Barc); 1997 Jun 20; 42(3):189-94. PubMed ID: 9381260
    [Abstract] [Full Text] [Related]

  • 9. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
    Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, Zahrieh D, Crombez E, Bhirangi K, Barton NW, Zimran A.
    Am J Hematol; 2013 Mar 20; 88(3):166-71. PubMed ID: 23386328
    [Abstract] [Full Text] [Related]

  • 10. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R, Arndt S, Levin JB.
    S Afr Med J; 2004 Aug 20; 94(8):647-51. PubMed ID: 15352589
    [Abstract] [Full Text] [Related]

  • 11. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
    Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE.
    N Engl J Med; 1991 May 23; 324(21):1464-70. PubMed ID: 2023606
    [Abstract] [Full Text] [Related]

  • 12. [Therapeutic targets in Gaucher's disease].
    Giraldo P, Roca M.
    Med Clin (Barc); 2011 Sep 23; 137 Suppl 1():46-9. PubMed ID: 22230126
    [Abstract] [Full Text] [Related]

  • 13. Enzyme replacement therapy for Gaucher disease in Australia.
    Goldblatt J, Szer J, Fletcher JM, McGill J, Rowell JA, Wilson M.
    Intern Med J; 2005 Mar 23; 35(3):156-61. PubMed ID: 15737135
    [Abstract] [Full Text] [Related]

  • 14. Rebound hepatosplenomegaly in type 1 Gaucher disease.
    Tóth J, Erdos M, Maródi L.
    Eur J Haematol; 2003 Feb 23; 70(2):125-8. PubMed ID: 12581195
    [Abstract] [Full Text] [Related]

  • 15. Failure of alglucerase infused into Gaucher disease patients to localize in marrow macrophages.
    Beutler E, Kuhl W, Vaughan LM.
    Mol Med; 1995 Mar 23; 1(3):320-4. PubMed ID: 8529110
    [Abstract] [Full Text] [Related]

  • 16. Improvement of splenomegaly and pancytopenia by enzyme replacement therapy against type 1 Gaucher disease: a report of sibling cases.
    Tsuboi K, Iida S, Kato M, Hayami Y, Hanamura I, Miura K, Harada S, Komatsu H, Banno S, Wakita A, Nitta M, Ueda R.
    Int J Hematol; 2001 Apr 23; 73(3):356-62. PubMed ID: 11345203
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.
    Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Elstein D, Paz A, Brill-Almon E, Chertkoff R.
    Blood Cells Mol Dis; 2015 Jan 23; 54(1):9-16. PubMed ID: 25453586
    [Abstract] [Full Text] [Related]

  • 18. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW.
    Blood Cells Mol Dis; 2000 Aug 23; 26(4):285-90. PubMed ID: 11042029
    [Abstract] [Full Text] [Related]

  • 19. Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease.
    Hollak CE, Corssmit EP, Aerts JM, Endert E, Sauerwein HP, Romijn JA, van Oers MH.
    Am J Med; 1997 Sep 23; 103(3):185-91. PubMed ID: 9316550
    [Abstract] [Full Text] [Related]

  • 20. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.
    Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, vom Dahl S, Hollak C.
    J Inherit Metab Dis; 2013 May 23; 36(3):543-53. PubMed ID: 22976765
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.